Epicardial adipose tissue as new cardio-metabolic risk marker and potential therapeutic target in the metabolic syndrome

Gianluca Iacobellis, Arya M. Sharma

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

Increased visceral adiposity, is an emerging cardiovascular risk factor. There is now a compelling need to quantify visceral adipose tissue not only for diagnostic purposes, but also for therapeutic interventions with weight reduction drugs or pharmaceuticals targeted to adipose tissue, as well as anti-obesity medications, thiazolidinediones, fibrates, angiotensin receptor blockers, highly active antiretroviral therapy and hormone replacement therapy. Among visceral adipose tissues, growing evidences suggest that cardiac adiposity may play an important role in the development of an unfavorable cardiovascular risk profile. Recent papers suggest that epicardial fat, index of cardiac and visceral adiposity, could locally modulate the morphology and function of the heart. The close anatomical relationship between epicardial adipose tissue and the adjacent myocardium should readily allow local paracrine interactions between these tissues. Echocardiography has been recently proposed for the direct assessment of epicardial adipose tissue. Echocardiographic assessment of epicardial fat may be a helpful tool not only for diagnostic purposes, as marker of visceral adiposity and inflammation, but also for therapeutic interventions with drugs that can modulate the adipose tissue. In this article, epicardial adipose tissue's structure, function, method of assessment and reliability as a diagnostic tool and potential therapeutic target is reviewed.

Original languageEnglish
Pages (from-to)2180-2184
Number of pages5
JournalCurrent Pharmaceutical Design
Volume13
Issue number21
DOIs
StatePublished - Jul 1 2007
Externally publishedYes

Fingerprint

Adiposity
Adipose Tissue
Intra-Abdominal Fat
Fats
Pharmaceutical Preparations
Fibric Acids
Therapeutics
Thiazolidinediones
Angiotensin Receptor Antagonists
Hormone Replacement Therapy
Highly Active Antiretroviral Therapy
Echocardiography
Weight Loss
Myocardium
Obesity
Inflammation

Keywords

  • Cardiac adiposity
  • Echocardiography
  • Epicardial adipose tissue
  • Epicardial fat
  • Therapeutic target

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Epicardial adipose tissue as new cardio-metabolic risk marker and potential therapeutic target in the metabolic syndrome. / Iacobellis, Gianluca; Sharma, Arya M.

In: Current Pharmaceutical Design, Vol. 13, No. 21, 01.07.2007, p. 2180-2184.

Research output: Contribution to journalArticle

@article{d22b311d07a1418b9203ef333881a382,
title = "Epicardial adipose tissue as new cardio-metabolic risk marker and potential therapeutic target in the metabolic syndrome",
abstract = "Increased visceral adiposity, is an emerging cardiovascular risk factor. There is now a compelling need to quantify visceral adipose tissue not only for diagnostic purposes, but also for therapeutic interventions with weight reduction drugs or pharmaceuticals targeted to adipose tissue, as well as anti-obesity medications, thiazolidinediones, fibrates, angiotensin receptor blockers, highly active antiretroviral therapy and hormone replacement therapy. Among visceral adipose tissues, growing evidences suggest that cardiac adiposity may play an important role in the development of an unfavorable cardiovascular risk profile. Recent papers suggest that epicardial fat, index of cardiac and visceral adiposity, could locally modulate the morphology and function of the heart. The close anatomical relationship between epicardial adipose tissue and the adjacent myocardium should readily allow local paracrine interactions between these tissues. Echocardiography has been recently proposed for the direct assessment of epicardial adipose tissue. Echocardiographic assessment of epicardial fat may be a helpful tool not only for diagnostic purposes, as marker of visceral adiposity and inflammation, but also for therapeutic interventions with drugs that can modulate the adipose tissue. In this article, epicardial adipose tissue's structure, function, method of assessment and reliability as a diagnostic tool and potential therapeutic target is reviewed.",
keywords = "Cardiac adiposity, Echocardiography, Epicardial adipose tissue, Epicardial fat, Therapeutic target",
author = "Gianluca Iacobellis and Sharma, {Arya M.}",
year = "2007",
month = "7",
day = "1",
doi = "10.2174/138161207781039670",
language = "English",
volume = "13",
pages = "2180--2184",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "21",

}

TY - JOUR

T1 - Epicardial adipose tissue as new cardio-metabolic risk marker and potential therapeutic target in the metabolic syndrome

AU - Iacobellis, Gianluca

AU - Sharma, Arya M.

PY - 2007/7/1

Y1 - 2007/7/1

N2 - Increased visceral adiposity, is an emerging cardiovascular risk factor. There is now a compelling need to quantify visceral adipose tissue not only for diagnostic purposes, but also for therapeutic interventions with weight reduction drugs or pharmaceuticals targeted to adipose tissue, as well as anti-obesity medications, thiazolidinediones, fibrates, angiotensin receptor blockers, highly active antiretroviral therapy and hormone replacement therapy. Among visceral adipose tissues, growing evidences suggest that cardiac adiposity may play an important role in the development of an unfavorable cardiovascular risk profile. Recent papers suggest that epicardial fat, index of cardiac and visceral adiposity, could locally modulate the morphology and function of the heart. The close anatomical relationship between epicardial adipose tissue and the adjacent myocardium should readily allow local paracrine interactions between these tissues. Echocardiography has been recently proposed for the direct assessment of epicardial adipose tissue. Echocardiographic assessment of epicardial fat may be a helpful tool not only for diagnostic purposes, as marker of visceral adiposity and inflammation, but also for therapeutic interventions with drugs that can modulate the adipose tissue. In this article, epicardial adipose tissue's structure, function, method of assessment and reliability as a diagnostic tool and potential therapeutic target is reviewed.

AB - Increased visceral adiposity, is an emerging cardiovascular risk factor. There is now a compelling need to quantify visceral adipose tissue not only for diagnostic purposes, but also for therapeutic interventions with weight reduction drugs or pharmaceuticals targeted to adipose tissue, as well as anti-obesity medications, thiazolidinediones, fibrates, angiotensin receptor blockers, highly active antiretroviral therapy and hormone replacement therapy. Among visceral adipose tissues, growing evidences suggest that cardiac adiposity may play an important role in the development of an unfavorable cardiovascular risk profile. Recent papers suggest that epicardial fat, index of cardiac and visceral adiposity, could locally modulate the morphology and function of the heart. The close anatomical relationship between epicardial adipose tissue and the adjacent myocardium should readily allow local paracrine interactions between these tissues. Echocardiography has been recently proposed for the direct assessment of epicardial adipose tissue. Echocardiographic assessment of epicardial fat may be a helpful tool not only for diagnostic purposes, as marker of visceral adiposity and inflammation, but also for therapeutic interventions with drugs that can modulate the adipose tissue. In this article, epicardial adipose tissue's structure, function, method of assessment and reliability as a diagnostic tool and potential therapeutic target is reviewed.

KW - Cardiac adiposity

KW - Echocardiography

KW - Epicardial adipose tissue

KW - Epicardial fat

KW - Therapeutic target

UR - http://www.scopus.com/inward/record.url?scp=34447515817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447515817&partnerID=8YFLogxK

U2 - 10.2174/138161207781039670

DO - 10.2174/138161207781039670

M3 - Article

VL - 13

SP - 2180

EP - 2184

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 21

ER -